The estimated Net Worth of Lise W Duran is at least $2.88 Milion dollars as of 25 February 2009. Lise Duran owns over 2,000 units of Surmodics stock worth over $2,294,053 and over the last 21 years Lise sold SRDX stock worth over $584,420.
Lise has made over 9 trades of the Surmodics stock since 2004, according to the Form 4 filled with the SEC. Most recently Lise sold 2,000 units of SRDX stock worth $36,080 on 25 February 2009.
The largest trade Lise's ever made was exercising 16,000 units of Surmodics stock on 17 August 2007 worth over $401,440. On average, Lise trades about 2,548 units every 89 days since 2004. As of 25 February 2009 Lise still owns at least 58,477 units of Surmodics stock.
You can see the complete history of Lise Duran stock trades at the bottom of the page.
Lise's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj a Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: